Another unusual “side effect” has been observed with semaglutide — the drug better known as Ozempic and Wegovy. Originally developed for type 2 diabetes, it proved effective for weight reduction, and now appears to benefit treatment of certain cancers. A University of California San Diego study reports that among people with colon cancer who were concurrently taking semaglutide, five-year mortality was 15.5%, whereas among those not taking it the figure was 37.1% — more than twice as high.
